Farmitalia Carlo Erba S.r.l.

Pharmacia & Upjohn

Pharmacia Italia S.p.a.

Marina Ripamonti

Antonino Suarato

Michele Caruso

Maria Cristina Geroni

Francesco Angelucci

Daniela Ruggieri

Laura Bersani

Cristina Geroni

Alberto Bargiotti

Maria Grandi

There are provided the combined use of 4-demethoxy-3&prime;-deamino-3&prime;-aziridinyl-4&prime;-methansulfonyl daunorubicin or 4-demethoxy-N,N-bis(2-chloroethyl)-4&prime;-methansulfonyl daunorubicin and an anti-neoplastic anti-mitotic compound and/or a platinum derivative in the treatment of tumors, as well as in the prevention or treatment of metastasis or in the treatment of tumors by inhibition of angiogenesis.

Anti-tumor synergetic composition

The present invention relates to combined preparations comprising a morpholinyl anthracycline administered in combination anticancer agents chosen from an alkylating agent, an antimetabolite, a topoisomerase II inihbitor, a topoisomerase I inhibitor, an antimitotic drug and a platinum derivative, which are useful anticancer therapy, particularly in the treatment of a primary or metastatic liver cancer.

Combined preparations comprising morpholine anthracyclines and anticancer agent

The present invention relates to combined preparations comprising a morpholinyl anthracycline administered in combination anticancer agents chosen from an alkylating agent, an antimetabolite, a topoisomerase II inhibitor, a topoisomerase I inhibitor, an antimitotic drug and a platinum derivative, which are useful anticancer therapy, particularly in the treatment of a primary or metastatic liver cancer.

The combination of 4-demethoxy-3&prime;-deamino-3&prime;-aziridinyl-4&prime;-methansulfonyl daunorubicin or 4-demethoxy-N,N-bis(2-chloroethyl)-4&prime;-methansulfonyl daunorubicin together with an antineoplastic topoisomerase I inhibitor yields preparations exhibiting anti-cancer effects. These preparations can be used in the treatment of tumors and especially 4-demethoxy-3&prime;-deamino-3&prime;-aziridinyl-4&prime;-methansulfonyl daunorubicin in the treatment of brain tumors.

Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate

The present invention relates to anthracycline glycosides, to a process for their preparation and to pharmaceutical compositions containing the same.

13-dihydro-3&prime; aziridino anthracyclines

Linker for bioactive agents

Anthracycline glycosides of general formula 1 and 2: ##STR1## wherein R.sub.1 is hydrogen or a methoxy group; R.sub.2 is hydrogen, a hydroxy group or represents an acyloxy residue of formula 3 --O--COR.sub.5 wherein R.sub.5 is a linear or branched C.sub.1 -C.sub.8 alkyl, an aryl group or a heterocyclic mono or bicyclic ring, each of which may be unsubstituted or substituted with (a) an amino group NR.sub.6 R.sub.7 in which R.sub.6 and R.sub.7 are independently hydrogen or C.sub.1 -C.sub.4 alkyl or (b) a carboxy group; R.sub.3 and R.sub.4 both represent hydrogen or one of R.sub.3 and R.sub.4 is hydrogen and the other is hydroxy group or a group of formula --OSO.sub.2 R.sub.8 in which R.sub.8 may be a linear or branched alkyl group containing from 1 to 6 carbon atoms or an aryl group unsubstituted or substituted by 1 to 3 substituents each of which may independently be a linear or branched alkyl or alkoxy group of from 1 to 6 carbon atoms, a halogen atom or a nitro group; and pharmaceutically acceptable salts thereof; are active as antitumor agents.

Growing community of inventors

Milan, Italy

Marina Ripamonti